デフォルト表紙
市場調査レポート
商品コード
1668441

mTOR阻害剤の世界市場レポート 2025年

mTOR Inhibitors Global Market Report 2025


出版日
ページ情報
英文 200 Pages
納期
2~10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
mTOR阻害剤の世界市場レポート 2025年
出版日: 2025年02月28日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

mTOR阻害剤の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.1%で99億米ドルに成長します。予測期間の成長は、がん領域の適応拡大、精密医療の進歩、移植症例の増加、慢性疾患管理、高齢者人口の増加などに起因すると考えられます。予測期間における世界の動向としては、神経保護作用の探索、移植医療での利用、代謝性疾患への関心の高まり、医薬品開発のための共同研究、希少疾患に対する世界ヘルスへの取り組みなどが挙げられます。

腎臓疾患の有病率の上昇は、mTOR阻害剤市場の拡大を大きく促進すると予想されます。これらの疾患は腎機能を徐々に悪化させるため、治療にはシロリムスやエベロリムスなどのmTOR阻害剤の使用が促されています。mTOR阻害剤を用いた免疫抑制療法は、腎移植後の拒絶反応の予防に重要な役割を果たしています。2022年4月に国際腎臓学会から発表された報告によると、世界全体で8億人以上(人口の10%)が慢性腎臓病に罹患しており、約8億4,360万人が腎臓病のステージ1から5に直面しています。急増するmTOR阻害剤市場の実質的な促進要因は、このような有病率の増加です。

世界のがん診断の急増は、mTOR阻害剤市場の拡大に大きな燃料を投じることになります。細胞増殖と生存の重要な調節因子であるmTOR経路の調節異常は、様々ながんでしばしば観察され、がんの進行に寄与しています。2023年2月に発表されたWorld Cancer Research Fund Internationalの予測によると、2040年までに世界のがん患者数は2,900万人近くまで増加すると予想されています。このような世界のがん診断の急増は、このような病態に対処する上でmTOR阻害剤が重要な役割を果たすことを強調し、結果として市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場:金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のmTOR阻害剤PESTEL分析(政治、社会、技術、環境、法的要因、促進要因、抑制要因)
  • 最終用途産業の分析
  • 世界のmTOR阻害剤市場:成長率分析
  • 世界のmTOR阻害剤市場の実績:規模と成長, 2019-2024
  • 世界のmTOR阻害剤市場の予測:規模と成長, 2024-2029, 2034F
  • 世界のmTOR阻害剤総アドレス可能市場(TAM)

第6章 市場セグメンテーション

  • 世界のmTOR阻害剤市場:製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ラパムネ
  • アフィニトール
  • トリセル
  • ゾートレス
  • その他の製品タイプ
  • 世界のmTOR阻害剤市場:適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • オンコロジー
  • 免疫抑制剤
  • 臓器移植
  • その他の適応症
  • 世界のmTOR阻害剤市場:投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • オーラル
  • 静脈内
  • 世界のmTOR阻害剤市場:用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 腫瘍治療
  • 腎臓移植
  • その他の用途
  • 世界のmTOR阻害剤市場:流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のmTOR阻害剤市場、タイプ別サブセグメンテーション:ラパムネ、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 移植
  • がん治療
  • 自己免疫疾患
  • 世界のmTOR阻害剤市場、タイプ別サブセグメンテーション:アフィニトール、実績と予測, 2019-2024, 2024-2029F, 2034F
  • オンコロジー
  • 臓器移植
  • 内分泌疾患
  • その他の疾患
  • 世界のmTOR阻害剤市場、タイプ別サブセグメンテーション:トリセル、実績と予測, 2019-2024, 2024-2029F, 2034F
  • オンコロジー
  • その他のがん
  • 世界のmTOR阻害剤市場、タイプ別サブセグメンテーション:ゾートレス、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 臓器移植
  • 移植後の免疫抑制
  • 世界のmTOR阻害剤市場、タイプ別サブセグメンテーション:その他の製品タイプ、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 臨床試験または実験mTOR阻害剤
  • mTOR阻害剤の複合語またはジェネリック語

第7章 地域別・国別分析

  • 世界のmTOR阻害剤市場:地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のmTOR阻害剤市場:国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • mTOR阻害剤市場:競合情勢
  • mTOR阻害剤市場:企業プロファイル
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Hikma Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
    • LC Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Exelixis Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Lifesciences Limited
  • Accord Healthcare Inc.
  • Par Pharmaceutical
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Biocon Limited
  • Alkem Laboratories Ltd.
  • Gland Pharma Ltd.
  • Apotex Inc.
  • Glenmark Pharmaceuticals Ltd.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • mTOR阻害剤市場2029:新たな機会を提供する国
  • mTOR阻害剤市場2029:新たな機会を提供するセグメント
  • mTOR阻害剤市場2029:成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r24350

mTOR inhibitors belong to a drug class that works by restraining the mTOR (mammalian/mechanistic target of rapamycin) protein, crucial in regulating cell division. This inhibition impedes cancer cell proliferation and thwarts the generation of new cells necessary for tumor growth.

Key products within the mTOR inhibitors category include Rapamune, Afinitor, Torise, Zortress, among others. Rapamune is a medication designed to prevent the rejection of organ and bone marrow transplants. Specifically, Rapamune, as an mTOR inhibitor, is prescribed for patients with lymphangioleiomyomatosis. These inhibitors find application across various medical domains including oncology, immunosuppression, and organ transplantation. They are administered through oral and intravenous routes and serve multiple purposes such as tumor treatment, kidney transplants, and more. Distribution channels for mTOR inhibitors encompass hospital pharmacies, retail pharmacies, and online pharmacies.

The mTOR inhibitors market research report is one of a series of new reports from The Business Research Company that provides mTOR inhibitors market statistics, including the mTOR inhibitors industry's global market size, regional shares, competitors with an mTOR inhibitors market share, detailed mTOR inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the mTOR inhibitors industry. This mTOR inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mTOR inhibitors market size has grown strongly in recent years. It will grow from$7.43 billion in 2024 to $7.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to oncology treatment advancements, renal cell carcinoma treatment, transplantation medicine, clinical research and drug development, immunosuppressive applications

The mTOR inhibitors market size is expected to see strong growth in the next few years. It will grow to $9.9 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to expanding oncology indications, advancements in precision medicine, rising transplantation cases, chronic disease management, increasing geriatric population. Major trends in the forecast period include exploration of neuroprotective effects, utilization in transplant medicine, rising interest in metabolic disorders, collaborations for drug development, global health initiatives for rare diseases.

The escalating prevalence of kidney diseases is anticipated to significantly drive the expansion of the mTOR inhibitors market. These diseases gradually deteriorate kidney function, prompting the use of mTOR inhibitors such as sirolimus and everolimus for treatment. Immunosuppressive therapies employing mTOR inhibitors play a crucial role in preventing rejection following renal transplantation. Reports from the International Society of Nephrology in April 2022 indicated that over 800 million individuals globally, accounting for 10% of the population, suffer from chronic renal disease, while approximately 843.6 million people face stages 1 to 5 of kidney diseases. This growing prevalence is a substantial driver behind the burgeoning mTOR inhibitors market.

The upsurge in cancer diagnoses worldwide is poised to significantly fuel the expansion of the mTOR inhibitor market. Dysregulation of the mTOR pathway, a key regulator of cell growth and survival, is often observed in various cancers, contributing to their progression. Projections from the World Cancer Research Fund International in February 2023 indicate an anticipated rise to almost 29 million global cancer cases by 2040. This surge in cancer diagnoses globally underscores the crucial role of mTOR inhibitors in addressing these conditions, consequently propelling the market's growth.

The burgeoning aging population is projected to substantially drive the growth of the mTOR inhibitor market. The rise in median age due to declining fertility rates and increased life expectancy has led to a higher prevalence of age-related ailments that can be targeted by mTOR inhibitors, such as cancer and Alzheimer's disease. Forecasts from the ARC Centre of Excellence in Population Ageing Research indicate a substantial increase in Australia's population aged 65 and above by 2041, rising by 54% compared to 2021. This demographic shift significantly contributes to the expanding market for mTOR inhibitors.

Collaboration and partnerships are emerging as prominent trends in the mTOR inhibitors market. Companies are forming alliances to gain traction in this sector. For example, in October 2022, Mirati Therapeutics, Inc. collaborated with Aadi Bioscience, Inc. to leverage a combination of drugs for patients with specific cancers. Another significant partnership occurred between Cambrian Biopharma and Novartis in February 2022, focusing on innovative compounds targeting the mTOR pathway. These collaborations aim to advance precision therapies and drive advancements in cancer treatments.

Major players in the mTOR inhibitor market are prioritizing product innovation, exemplified by the introduction of FYARRO. FYARRO, developed by Aadi Bioscience, Inc., is a prescription medicine for treating malignant perivascular epithelioid cell tumors (PEComa) in adults. Approved in November 2022, FYARRO is the first approved therapy for this rare and aggressive sarcoma, marking a significant advancement in addressing this condition.

Major companies operating in the mTOR inhibitors market include Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, LC Laboratories, Exelixis Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Accord Healthcare Inc., Par Pharmaceutical, AbbVie Inc., GlaxoSmithKline plc, Biocon Limited, Alkem Laboratories Ltd., Gland Pharma Ltd., Apotex Inc., Glenmark Pharmaceuticals Ltd., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co. Inc., AmpliPhi Biosciences Corporation, Melinta Therapeutics Inc., Aduro Biotech Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH

North America was the largest region in the mTOR inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mtor inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the mtor inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The mTOR inhibitor market consists of sales of branded and generic mTOR inhibitor tablets and capsules. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

mTOR Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mtor inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mtor inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mtor inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Rapamune; Afinitor; Torisel; Zortress; Other Product Types
  • 2) By Indication: Oncology; Immunosuppressant; Organ Transplantation; Other Indications
  • 3) By Route of Administration: Oral; Intravenous
  • 4) By Application: Tumor Treatment; Kidney Transplant; Other Applications
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Rapamune: Dosage Forms; Indications
  • 2) By Afinitor: Dosage Forms; Indications
  • 3) By Torisel: Dosage Forms; Indications
  • 4) By Zortress: Dosage Forms; Indications
  • 5) By Other Product Types: Experimental MTOR Inhibitors; Generic Versions of MTOR Inhibitors; Combination Therapies with MTOR Inhibitors
  • Companies Mentioned: Novartis AG; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Hikma Pharmaceuticals plc; LC Laboratories
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. mTOR Inhibitors Market Characteristics

3. mTOR Inhibitors Market Trends And Strategies

4. mTOR Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global mTOR Inhibitors Growth Analysis And Strategic Analysis Framework

  • 5.1. Global mTOR Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global mTOR Inhibitors Market Growth Rate Analysis
  • 5.4. Global mTOR Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global mTOR Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global mTOR Inhibitors Total Addressable Market (TAM)

6. mTOR Inhibitors Market Segmentation

  • 6.1. Global mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rapamune
  • Afinitor
  • Torisel
  • Zortress
  • Other Product Types
  • 6.2. Global mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Immunosuppressant
  • Organ Transplantation
  • Other Indications
  • 6.3. Global mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • 6.4. Global mTOR Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tumor Treatment
  • Kidney Transplant
  • Other Applications
  • 6.5. Global mTOR Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.6. Global mTOR Inhibitors Market, Sub-Segmentation Of Rapamune, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transplantation
  • Cancer Therapy
  • Autoimmune Diseases
  • 6.7. Global mTOR Inhibitors Market, Sub-Segmentation Of Afinitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Organ Transplantation
  • Endocrine Disorders
  • Other Diseases
  • 6.8. Global mTOR Inhibitors Market, Sub-Segmentation Of Torisel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Other Cancers
  • 6.9. Global mTOR Inhibitors Market, Sub-Segmentation Of Zortress, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Organ Transplantation
  • Post-Transplantation Immunosuppression
  • 6.10. Global mTOR Inhibitors Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinical Trials or Experimental mTOR Inhibitors
  • Compounded or Generic Formulations of mTOR Inhibitors

7. mTOR Inhibitors Market Regional And Country Analysis

  • 7.1. Global mTOR Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global mTOR Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific mTOR Inhibitors Market

  • 8.1. Asia-Pacific mTOR Inhibitors Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China mTOR Inhibitors Market

  • 9.1. China mTOR Inhibitors Market Overview
  • 9.2. China mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India mTOR Inhibitors Market

  • 10.1. India mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan mTOR Inhibitors Market

  • 11.1. Japan mTOR Inhibitors Market Overview
  • 11.2. Japan mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia mTOR Inhibitors Market

  • 12.1. Australia mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia mTOR Inhibitors Market

  • 13.1. Indonesia mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea mTOR Inhibitors Market

  • 14.1. South Korea mTOR Inhibitors Market Overview
  • 14.2. South Korea mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe mTOR Inhibitors Market

  • 15.1. Western Europe mTOR Inhibitors Market Overview
  • 15.2. Western Europe mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK mTOR Inhibitors Market

  • 16.1. UK mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany mTOR Inhibitors Market

  • 17.1. Germany mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France mTOR Inhibitors Market

  • 18.1. France mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy mTOR Inhibitors Market

  • 19.1. Italy mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain mTOR Inhibitors Market

  • 20.1. Spain mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe mTOR Inhibitors Market

  • 21.1. Eastern Europe mTOR Inhibitors Market Overview
  • 21.2. Eastern Europe mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia mTOR Inhibitors Market

  • 22.1. Russia mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America mTOR Inhibitors Market

  • 23.1. North America mTOR Inhibitors Market Overview
  • 23.2. North America mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA mTOR Inhibitors Market

  • 24.1. USA mTOR Inhibitors Market Overview
  • 24.2. USA mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada mTOR Inhibitors Market

  • 25.1. Canada mTOR Inhibitors Market Overview
  • 25.2. Canada mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America mTOR Inhibitors Market

  • 26.1. South America mTOR Inhibitors Market Overview
  • 26.2. South America mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil mTOR Inhibitors Market

  • 27.1. Brazil mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East mTOR Inhibitors Market

  • 28.1. Middle East mTOR Inhibitors Market Overview
  • 28.2. Middle East mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa mTOR Inhibitors Market

  • 29.1. Africa mTOR Inhibitors Market Overview
  • 29.2. Africa mTOR Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa mTOR Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa mTOR Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. mTOR Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. mTOR Inhibitors Market Competitive Landscape
  • 30.2. mTOR Inhibitors Market Company Profiles
    • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Hikma Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. LC Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. mTOR Inhibitors Market Other Major And Innovative Companies

  • 31.1. Exelixis Inc.
  • 31.2. Dr. Reddy's Laboratories Ltd.
  • 31.3. Zydus Lifesciences Limited
  • 31.4. Accord Healthcare Inc.
  • 31.5. Par Pharmaceutical
  • 31.6. AbbVie Inc.
  • 31.7. GlaxoSmithKline plc
  • 31.8. Biocon Limited
  • 31.9. Alkem Laboratories Ltd.
  • 31.10. Gland Pharma Ltd.
  • 31.11. Apotex Inc.
  • 31.12. Glenmark Pharmaceuticals Ltd.
  • 31.13. AstraZeneca plc
  • 31.14. Bristol-Myers Squibb Company
  • 31.15. Eli Lilly and Company

32. Global mTOR Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The mTOR Inhibitors Market

34. Recent Developments In The mTOR Inhibitors Market

35. mTOR Inhibitors Market High Potential Countries, Segments and Strategies

  • 35.1 mTOR Inhibitors Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 mTOR Inhibitors Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 mTOR Inhibitors Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer